These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2530502)

  • 21. Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):279-87. PubMed ID: 7030975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of guanfacine on blood pressure and renin activity in hypertensive patients.
    Rosenthal J
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):91S-96S. PubMed ID: 6994787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic effects of guanfacine in essential hypertension.
    Feldstein CA; Cohen AA; Sabaris RP; Burucúa JE
    Clin Ther; 1984; 6(3):325-34. PubMed ID: 6373009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of guanfacine in the treatment of arterial hypertension].
    de Broucker D; Graux P; Dutoit A; Croccel L
    LARC Med; 1982; 2(7):613-5. PubMed ID: 6762476
    [No Abstract]   [Full Text] [Related]  

  • 26. [A clinical study of guanfacine in the treatment of arterial hypertension].
    Kheder A; Souilem J; Hassine L; Ben Maiz H; Ben Moussa F; Ben Ayed H
    Tunis Med; 1987 Nov; 65(11):709-12. PubMed ID: 3332951
    [No Abstract]   [Full Text] [Related]  

  • 27. [Guanfacine versus alpha-methyldopa in benign essential hypertension. An ambulatory group study].
    Rhomberg F; Widler J
    Schweiz Med Wochenschr; 1981 Dec; 111(50):1967-8. PubMed ID: 7036334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A new antihypertensive agent used in a clinical setting].
    Wetzels E; Raschig A; Kaiser HJ
    Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of long-term treatment of essential hypertension with guanfacine.
    Higuchi M; Overlack A; Stumpe KO
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):61S-64S. PubMed ID: 6994780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adrenergic and dopaminergic regulation of circulating beta-endorphin-like immunoreactivity in hypertension.
    Alföldi A; Simkó K; Fekete MI; Farsang C
    Acta Physiol Hung; 1991; 78(1):99-106. PubMed ID: 1763654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension.
    Mayer O; Polívková H
    Cor Vasa; 1987; 29(4 Suppl 1):37-41. PubMed ID: 3315449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical studies with captopril treatment of hypertensive patients.
    Varga K; Alföldi S; Kiss I; Simkó K; Farsang C
    Acta Physiol Hung; 1988; 72 Suppl():67-78. PubMed ID: 2855293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A postmarketing evaluation of guanfacine hydrochloride in mild to moderate hypertension.
    Board AW; Perry VP; Shepperson BE; Nyman CE; Carchman SH
    Clin Ther; 1988; 10(6):761-75. PubMed ID: 3064907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of treatment with enalapril maleate on the levels of circulating catecholamines, beta endorphins, prostaglandins, and concentration of sodium in erythrocytes in patients with essential hypertension].
    Chodakowska J; Wocial B; Ignatowska-Switalska H; Knypl K; Brym E; Czerniewska E; Wacławek-Maczkowska J; Jabłońska-Skwiecińska E; Drygieniec D; Januszewicz W
    Pol Tyg Lek; 1989 Mar 20-27; 44(12-13):297-300. PubMed ID: 2554261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Improvement of the functional capacity of hypertensive patients treated with guanfacine].
    Bazika V; Neuzil P; Tiserová J; Hrabovský F
    Cas Lek Cesk; 1986 May; 125(21):637-40. PubMed ID: 3518943
    [No Abstract]   [Full Text] [Related]  

  • 36. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antihypertensive therapy with guanfacine. A multicenter study with Estulic-Wander 1mg. Determinants of effectiveness and tolerance].
    Schäfer N; Knaup G
    Med Welt; 1983 Feb; 34(5):158-61. PubMed ID: 6341756
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guanfacine in the treatment of arterial hypertension. Apropos of 471 cases in a hospital milieu].
    Carette B
    Ann Cardiol Angeiol (Paris); 1984; 33(2):123-6. PubMed ID: 6143529
    [No Abstract]   [Full Text] [Related]  

  • 40. Low dose guanfacine and methyldopa in mild essential hypertension. A multiple centre study.
    Viskoper RJ; Laszt A; Paran E; Ben Ari J; Goren Y; Modan M
    Neth J Med; 1987 Aug; 31(1-2):58-65. PubMed ID: 3309693
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.